Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic peripheral neuropathy responsive to rituximab.

John J Kelly1

  • 1Department of Neurology, The George Washington University Medical Center, Washington, DC, USA.

Reviews in Neurological Diseases
|July 5, 2006
PubMed
Summary

A 73-year-old man with neuropathy secondary to IgM antibodies against myelin-associated glycoprotein experienced significant gait improvement after rituximab treatment. This therapy offered a viable option when standard treatments were unsuitable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implanted dynamic electric field therapy for glioblastoma: preclinical safety and efficacy of intratumoral modulation therapy.

Neuro-oncology advances·2026
Same author

Capsular Contributions to Hip Joint Stability: Clinical Anatomy and Implications for Surgical Management.

Clinical anatomy (New York, N.Y.)·2026
Same author

To Trim or Not to Trim: Revisiting Acetabuloplasty During Hip Arthroscopy for Femoroacetabular Impingement and Acetabular Overcoverage.

Current reviews in musculoskeletal medicine·2026
Same author

Linking tumor viability and immune infiltration with dual-nucleus MRI in preclinical models.

Npj imaging·2026
Same author

Early Discontinuation of Long-Term Anticoagulation After Surgical Left Atrial Appendage Occlusion.

The Annals of thoracic surgery·2026
Same author

Evidence-Based Risk Factors for Failure of Arthroscopic Labral Repair.

Current reviews in musculoskeletal medicine·2026

Area of Science:

  • Neurology
  • Immunology

Background:

  • Monoclonal IgM gammopathy can cause demyelinating polyneuropathy.
  • Myelin-associated glycoprotein (MAG) is a key target in certain autoimmune neuropathies.

Observation:

  • A 73-year-old male presented with progressive sensory and gait disturbances over 3 years.
  • Neurological work-up revealed abnormal electromyogram and positive anti-MAG IgM antibodies, confirming neuropathy.
  • Standard treatments were contraindicated due to patient's health and deficit severity.

Findings:

  • Rituximab therapy (375 mg/m2 weekly for 4 weeks) was administered.
  • Patient showed progressive improvement in gait and sensory symptoms post-treatment.
  • Within 3 months, the patient no longer required ambulatory aids and returned to work.

Implications:

  • Rituximab represents a potential therapeutic option for anti-MAG neuropathy, especially when conventional treatments are not feasible.
  • This case highlights the efficacy of B-cell depletion therapy in managing specific autoimmune neuropathies.
  • Successful treatment can lead to significant functional recovery and improved quality of life.

Related Experiment Videos